Corticosteroid outcome may be dependent of duration of use in severe COVID-19
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: For patients hospitalized with coronavirus disease 2019 (COVID-19) who require supplemental oxygen, the evidence of the optimal duration of corticosteroid is limited. This study aims to identify whether long-term use of corticosteroids is associated with decreased mortality. Methods: Between February 10, 2020 and October 31, 2021, we analyzed consecutive hospitalized patients with COVID-19 with severe hypoxemia. The patients were divided into short-term (≤ 14 days) and long-term (> 14 days) corticosteroid users. The primary outcome was 60-day mortality. We performed propensity score (PS) analysis to mitigate the effect of confounders and conducted Kaplan-Meier curve analysis. Results: There were 141 (52%) short-term users and 130 (48%) long-term corticosteroid users. The median age was 68 years and the median PaO2/FiO2 at admission was 158. Of the patients, 40.6% required high-flow nasal cannula, 48.3% required mechanical ventilation, and 11.1% required extracorporeal membrane oxygenation. The overall 60-day mortality rate was 23.2%, and that of patients with hospital-acquired pneumonia (HAP) was 22.9%. The Kaplan-Meier curve for 60- day survival in the PS-matched cohort showed that corticosteroid for > 14 days was associated with decreased mortality (p = 0.0033). There were no significant differences in bacteremia and HAP between the groups. An adjusted odds ratio for the risk of 60-day mortality in short-term users was 5.53 (95% confidence interval, 1.90–18.26; p = 0.003). Conclusions: For patients with severe COVID-19, long-term use of corticosteroids was associated with decreased mortality, with no increase in nosocomial complications. Corticosteroid use for > 14 days can benefit patients with severe COVID-19.
Abstract
Background/Aims: For patients hospitalized with coronavirus disease 2019 (COVID-19) who require supplemental oxygen, the evidence of the optimal duration of corticosteroid is limited. This study aims to identify whether long-term use of corticosteroids is associated with decreased mortality. Methods: Between February 10, 2020 and October 31, 2021, we analyzed consecutive hospitalized patients with COVID-19 with severe hypoxemia. The patients were divided into short-term (≤ 14 days) and long-term (> 14 days) corticosteroid users. The primary outcome was 60-day mortality. We performed propensity score (PS) analysis to mitigate the effect of confounders and conducted Kaplan-Meier curve analysis. Results: There were 141 (52%) short-term users and 130 (48%) long-term corticosteroid users. The median age was 68 years and the median PaO2/FiO2 at admission was 158. Of the patients, 40.6% required high-flow nasal cannula, 48.3% required mechanical ventilation, and 11.1% required extracorporeal membrane oxygenation. The overall 60-day mortality rate was 23.2%, and that of patients with hospital-acquired pneumonia (HAP) was 22.9%. The Kaplan-Meier curve for 60- day survival in the PS-matched cohort showed that corticosteroid for > 14 days was associated with decreased mortality (p = 0.0033). There were no significant differences in bacteremia and HAP between the groups. An adjusted odds ratio for the risk of 60-day mortality in short-term users was 5.53 (95% confidence interval, 1.90–18.26; p = 0.003). Conclusions: For patients with severe COVID-19, long-term use of corticosteroids was associated with decreased mortality, with no increase in nosocomial complications. Corticosteroid use for > 14 days can benefit patients with severe COVID-19.
참고문헌 (45)
- Ackermann M, "Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19", N Engl J Med, 383, pp.120~128 (2020)
- Wiersinga WJ, "Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019(COVID-19) : a review", JAMA, 324, pp.782~793 (2020)
- Fajgenbaum DC, "Cytokine storm", N Engl J Med, 383, pp.2255~2273 (2020)
- RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with covid-19", N Engl J Med, 384, pp.693~704 (2021)
- REMAP-CAP Investigators, "Interleukin-6 receptor antagonists in critically ill patients with covid-19", N Engl J Med, 384, pp.1491~1502 (2021)
- Kalil AC, "Baricitinib plus remdesivir for hospitalized adults with covid-19", N Engl J Med, 384, pp.795~807 (2021)
- "Coronavirus disease 2019 (COVID-19) treatment guidelines" (2022)[URL]
- Arabi YM, "The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19", Intensive Care Med, 46, pp.2067~2070 (2020)
- Joly BS, "Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19", Intensive Care Med, 46, pp.1603~1606 (2020)
- Vargas A, "Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma", Respir Res, 18, pp.207~ (2017)
- Fleishaker DL, "Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects : a dose ranging, randomized, placebo-controlled, crossover study", BMC Musculoskelet Disord, 17, pp.293~ (2016)
- Meduri GU, "Methylprednisolone infusion in early severe ARDS : results of a randomized controlled trial", Chest, 131, pp.954~963 (2007)
- COVID STEROID 2 Trial Group, "Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia : the COVID STEROID 2 randomized trial", JAMA, 326, pp.1807~1817 (2021)
- Granholm A, "Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia : a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial", Intensive Care Med, 48, pp.45~55 (2022)
- Dequin PF, "Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19 : a randomized clinical trial", JAMA, 324, pp.1298~1306 (2020)
- Tomazini BM, "Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19 : the CoDEX randomized clinical trial", JAMA, 324, pp.1307~1316 (2020)
- Angus DC, "Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19 : the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial", JAMA, 324, pp.1317~1329 (2020)
- Corral-Gudino L, "Methylprednisolone in adults hospitalized with COVID-19 pneumonia : an open-label randomized trial(GLUCOCOVID)", Wien Klin Wochenschr, 133, pp.303~311 (2021)
- Ranjbar K, "Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients : a triple-blinded randomized controlled trial", BMC Infect Dis, 21, pp.337~ (2021)
- Rubio-Rivas M, "WHO ordinal scale and inflammation risk categories in COVID-19. Comparative study of the severity scales", J Gen Intern Med, 37, pp.1980~1987
- Liu D, "A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy", Allergy Asthma Clin Immunol, 9, pp.30~ (2013)
- Prowle JR, "Acquired bloodstream infection in the intensive care unit : incidence and attributable mortality", Crit Care, 15, pp.R100~ (2011)
- Kalil AC, "Management of adults with hospital-acquired and ventilator-associated pneumonia : 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society", Clin Infect Dis, 63, pp.e61~e111 (2016)
- Moreno G, "Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome(ARDS)patients : a multicentre cohort study", Ann Intensive Care, 11, pp.159~ (2021)
- Ye Z, "Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome : a systematic review and meta-analysis", CMAJ, 192, pp.E756~E767 (2020)
- WHO Rapid Evidence Appraisal for COVID-19 Therapies(REACT)Working Group, "Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19 : a meta-analysis", JAMA, 324, pp.1330~1341 (2020)
- Cano EJ, "Impact of corticosteroids in coronavirus disease 2019 outcomes : systematic review and meta-analysis", Chest, 159, pp.1019~1040 (2021)
- Carsana L, "Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy : a two-centre descriptive study", Lancet Infect Dis, 20, pp.1135~1140 (2020)
- Schaller T, "Postmortem examination of patients with COVID-19", JAMA, 323, pp.2518~2520 (2020)
- Meduri GU, "Prolonged glucocorticoid treatment is associated with improved ARDS outcomes : analysis of individual patients’data from four randomized trials and trial-level meta-analysis of the updated literature", Intensive Care Med, 42, pp.829~840 (2016)
- Chaudhuri D, "Corticosteroids in COVID-19 and non-COVID-19 ARDS : a systematic review and meta-analysis", Intensive Care Med, 47, pp.521~537 (2021)
- Meduri GU, "Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS", Intensive Care Med, 46, pp.2284~2296 (2020)
- Kostorz-Nosal S, "A prolonged steroid therapy may be beneficial in some patients after the COVID-19 pneumonia", Eur Clin Respir J, 8, pp.1945186~ (2021)
- Myall KJ, "Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment", Ann Am Thorac Soc, 18, pp.799~806 (2021)
- Seo Hyeonji, "Radiologically Suspected Organizing Pneumonia in a Patient Recovering from COVID-19: A Case Report", Infection and Chemotherapy, 54(1), pp.208~212 (2022), 대한감염학회[DOI]
- Bieksiene K, "Post COVID-19 organizing pneumonia:the right time to interfere", Medicina(Kaunas), 57, pp.283~ (2021)
- Kory P, "SARS-CoV-2 organising pneumonia : ‘has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’", BMJ Open Respir Res, 7, pp.e000724~ (2020)
- Golbets E, "Secondary organizing pneumonia after recovery of mild COVID-19 infection", J Med Virol, 94, pp.417~423 (2022)
- Cordier JF, "Organising pneumonia", Thorax, 55, pp.318~328 (2000)
- Cordier JF, "Cryptogenic organising pneumonia", Eur Respir J, 28, pp.422~446 (2006)
- Patel A, "A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India", Clin Microbiol Infect, 26, pp.944~ (2020)
- Hirano Y, "Corticosteroid treatment for early acute respiratory distress syndrome : a systematic review and meta-analysis of randomized trials", J Intensive Care, 8, pp.91~ (2020)
- Griffiths MJD, "Guidelines on the management of acute respiratory distress syndrome", BMJ Open Respir Res, 6, pp.e000420~ (2019)
- Brotman DJ, "Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers", Thromb Res, 118, pp.247~252 (2006)
- Mishra GP, "Corticosteroids for COVID-19 : the search for an optimum duration of therapy", Lancet Respir Med, 9, pp.e8~ (2021)